Home » Stocks » Acceleron Pharma

Acceleron Pharma, Inc. (XLRN)

Stock Price: $97.67 USD -1.45 (-1.46%)
Updated Aug 10, 2020 11:52 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 5.80B
Revenue (ttm) 87.64M
Net Income (ttm) -138.33M
Shares Out 59.90M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $97.67
Previous Close $99.12
Change ($) -1.45
Change (%) -1.46%
Day's Open 99.02
Day's Range 96.95 - 100.55
Day's Volume 146,344
52-Week Range 37.60 - 110.75

More Stats

Market Cap 5.80B
Enterprise Value 5.44B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 59.90M
Float 52.53M
EPS (basic) -2.59
EPS (diluted) -2.60
FCF / Share -2.73
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.35M
Short Ratio 2.78
Short % of Float 7.01%
Beta 0.74
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 66.22
PB Ratio 15.30
Revenue 87.64M
Operating Income -144.99M
Net Income -138.33M
Free Cash Flow -147.13M
Net Cash 366.40M
Net Cash / Share 6.17
Gross Margin -91.23%
Operating Margin -165.43%
Profit Margin -157.80%
FCF Margin -167.88%
ROA -17.59%
ROE -30.02%
ROIC -57.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 10
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(29.69% upside)
Current: $97.67
Target: 126.67
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth428.86%3.78%-51.46%53.46%23.68%-74.43%275.18%-81.15%-
Gross Profit73.9913.9913.4827.7718.1014.6357.2315.2579.41
Operating Income-136-124-110-66.11-60.88-55.466.95-28.8938.56
Net Income-125-119-108-57.01-63.89-51.26-21.90-32.5870.42
Shares Outstanding52.4545.9040.4237.4333.3031.529.412.402.33
Earnings Per Share-2.38-2.59-2.68-1.52-1.92-1.63-4.15-24.840.78
Operating Cash Flow-93.80-94.71-76.54-44.55-44.21-53.22-19.65-38.889.06
Capital Expenditures-3.29-2.59-4.40-3.38-0.96-0.51-0.31-0.44-0.03
Free Cash Flow-97.09-97.30-80.94-47.93-45.17-53.73-19.96-39.339.03
Cash & Equivalents43129127814110617711440.5265.95
Total Debt26.38-----16.8720.196.00
Net Cash / Debt40529127814110617797.2120.3359.95
Book Value44929236522610915657.81-291-233
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Acceleron Pharma, Inc.
Country United States
Employees 237
CEO Habib J. Dable

Stock Information

Ticker Symbol XLRN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XLRN
IPO Date September 19, 2013


Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.